Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Herbalife

Weightwatchers International Inc.

Weight-loss and nutrition companies have lost half or more of their value in the past year despite expectations of a postpandemic boom.

Losing Weight Is Losing Ground in the Stock Market

It is a consistently profitable growth company that was recognized by Fortune and Forbes several times. Yet, the stock has crashed over 64% since it peaked on 1st May 2021, falling from $332.25 to $119.05 as of 2 September 2022.

Medifast: Would Chuck Akre Approve?

BALTIMORE , Sept. 8, 2022 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA® , announced today that Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer, will meet with investors and participate in a fireside chat at the Jefferies Virtual Fitness & Wellness Summit, to be held September 12, 2022.

Medifast, Inc. to Present at the Jefferies Virtual Fitness & Wellness Summit

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Why Is Medifast (MED) Down 19.8% Since Last Earnings Report?

Medifast (MED) has been seeing high SG&A expenses and escalated raw material costs. The company expects short-term margin pressure in 2022 due to inflation and continued investments.

Medifast (MED) Down More Than 20% in 3 Months on Cost Woes

Medifast's stock plummeted 16% after reporting Q2 earnings. Both earnings and revenue beat analysts' consensus but guidance was cut significantly.

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Medifast's (MED) second-quarter 2022 results reflect increased active earning OPTAVIA Coaches and elevated costs. Management cuts guidance for 2022 due to inflation.

Medifast (MED) Q2 Earnings Top Estimates, Guidance Lowered

Medifast, Inc. (NYSE:MED ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Reed Anderson - ICR, Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Chris Neamonitis - Jefferies Operator Good afternoon. And welcome to Medifast Second Quarter 2022 Earnings Conference Call.

Medifast, Inc. (MED) CEO Dan Chard on Q2 2022 Results - Earnings Call Transcript

Medifast (MED) delivered earnings and revenue surprises of 17.99% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Surpasses Q2 Earnings Estimates

BALTIMORE , Aug. 3, 2022 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities,  OPTAVIA® , today reported results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights Compared to the Prior-Year Period Revenue increased 15.0% to $453.3 million 14.9% growth in the number of independent active earning OPTAVIA Coaches to 68,000 Revenue per active earning OPTAVIA Coach was $6,667 a slight increase above the prior year Net income decreased 16.7% to $39.1 million Non-GAAP adjusted net income decreased 5.7% to $44.3 million Earnings per diluted share ("EPS") of $3.42, a decrease of 13.6% Non-GAAP adjusted EPS of $3.87, a 2.5% decrease Entered into a $100 million accelerated share repurchase agreement "We delivered another solid quarter at Medifast, with revenues up 15%, almost 15% growth in the number of active earning Coaches, and robust Coach productivity.

Medifast Announces Second Quarter 2022 Financial Results and Updated Outlook

Expeditors International of Washington

Hudson Global

Skyline Corp.

Universal Forest Products

Do you have more faith in DuPont analysis than simple ROE calculation? Tap UFP Industries (UFPI), MEDIFAST (MED), Skyline (SKY), Hudson Global (HSON) and Expeditors International of Washington (EXPD).

Explore DuPont Analysis & Pick 5 Top Stocks

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Medifast (MED) have what it takes?

Medifast (MED) is a Top Dividend Stock Right Now: Should You Buy?

Immersive event dedicated to shaping the future of Optimal Health draws sold-out crowd in Atlanta BALTIMORE , July 25, 2022 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA , held its annual OPTAVIA Convention from July 21-23. More than 17,000 people registered for the global event, which drew a sold-out crowd to State Farm Arena in Atlanta as well as thousands more who joined virtually.

Over 17,000 Registered for Flagship OPTAVIA Event Following Year of Rapid Growth

Expansion of expert panel builds on company's strong scientific heritage as it sets sights on broader $230 billion health and wellness industry BALTIMORE , July 21, 2022 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA ®, announced today the addition of three new members to its long-standing Scientific Advisory Board: Dr. Nikhil Dhurandhar, Dr. Graham Thomas and Dr. Jessica Unick. Medifast's Scientific Advisory Board is now comprised of seven internationally recognized experts who provide objective insights to guide the company in making informed decisions based on the latest scientific developments in health and wellness.

Medifast Announces New Scientific Advisory Board Appointments

This is Why Medifast (MED) is a Great Dividend Stock

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is MEDIFAST (MED) Stock Undervalued Right Now?

MED is one of the few stocks which combines good characteristics of value, growth, and dividend stocks. Measured at its historic multiples and the multiples of the sector, the MED stock is undervalued right now.

Medifast: Generating Well-Being For Both Customers And Shareholders

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Medifast (MED) is a Top Momentum Stock for the Long-Term

Medifast, Inc. is a fast-growing company that continues to generate increasing profits and excellent returns for investors. In addition to solid growth, the company offers a hefty dividend.

Medifast And Its Real Value

Medifast (MED) could produce exceptional returns because of its solid growth attributes.

Is Medifast (MED) a Solid Growth Stock? 3 Reasons to Think "Yes"

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Medifast (MED) is a Top Growth Stock for the Long-Term

Medifast (MED) has been gaining from its OPTAVIA lifestyle solution and coaching support system due to consumers' rising inclination toward health.

Medifast (MED) Benefits From Solid OPTAVIA Lifestyle Solution

Medifast survey reveals lack of time and support are consumers' biggest barriers BALTIMORE , June 21, 2022 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA®, today announced findings from a company-sponsored survey* exploring U.S. adults' dieting patterns and perspectives on health. According to the survey, 70% of U.S. adults consider their health to be a top priority in life, the most common response even ahead of family and career.

Health is Top Priority for Majority of U.S. Adults Despite Continuous Cycle of Failed Diets

Arbor Realty Trust

Agnico Eagle Mines

Alico

Ally Financial

Yamana Gold

Best Buy

Big 5 Sporting Goods

Escalade

Fidelity National Financial

Gilead Sciences

Hooker Furniture

Leggett & Platt

Lennox International

Masco

MPLX

Pan American Silver

Prudential Financial

Sirius XM Holdings Inc

Universal Corp

Vici Properties

Whirlpool

Western Union

June 2022, The AAII Journal listed two sets of stocks sorted as: High-Yielding Dividend Payers, and Biggest Rising Dividend Payers. Those two articles revealed 40 dividend-paying-equities. The American Association of Individual Investors (AAII) is an independent non-profit corporation assisting individual investors through programs of education, information, and research.

14 June High-Yield And High-Rising Dividend Dogs Ready To Buy

BALTIMORE , June 16, 2022 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities,  OPTAVIA® , announced today that its Board of Directors has declared a $1.64 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.64 per share is payable on August 8, 2022 to stockholders of record as of the close of business on June 28, 2022.

News for Medifast Stock (MED)